#United States #Veeva Systems #Pleasanton #DNAnexus #Accumulus Technologies

Veeva RIM: Driving Innovation and Efficiency in Biopharma

In a significant move for the biopharmaceutical industry, Veeva Systems has reported that a staggering 19 out of the top 20 global biopharma companies have implemented its regulatory information management tool, Veeva RIM. This development comes as over 450 companies are now relying on this integrated platform to accelerate the drug approval process, thereby enhancing efficiency in regulatory practices.

Veeva Systems, headquartered in Pleasanton, California, aims to elevate connectivity through continuous innovations. This includes strategic partnerships with Accumulus Technologies and DNAnexus, which facilitate seamless integration with multiple health authority platforms. Such collaborations improve compliance and operational efficiency for companies navigating complex regulatory landscapes.

Marc Gabriel, Veeva’s Vice President of Regulatory Affairs, emphasized the ongoing adoption of Veeva’s product innovations by regulatory teams seeking continuous improvement in efficiency and reduced cycle times. He stated, “Enhanced by industry partnerships, Veeva RIM offers a comprehensive solution that shortens time to market and improves collaboration with global stakeholders, enabling seamless data flow in rapidly evolving regulatory environments.”

The impact of Veeva RIM is particularly pronounced among the 85 organizations utilizing Veeva Submissions Publishing. These companies benefit from ongoing publishing capabilities that significantly reduce rework and bottleneck issues, leading to shorter application timelines.

Francisco Nogueira, CEO of Accumulus Technologies, shared insights into their strategic partnership, which seeks to enhance interoperability between the Accumulus platform and Veeva RIM. He noted that this collaboration modernizes the process of sharing information in real-time across a growing network of over 70 regulatory authorities. “By promoting seamless regulatory submissions, our customers can deliver therapies to patients even faster,” he remarked.

In a similar vein, DNAnexus CEO Thomas Laur stressed the importance of their integration of Trusted Regulatory Spaces (TRS) with Veeva RIM, promising superior data sharing capabilities that facilitate inter-agency collaboration and swift approval of regulated products.

The Veeva RIM platform, built on Veeva's Development Cloud infrastructure, streamlines global regulatory processes on a single cloud-based platform, addressing the technical foundation essential to product development across clinical, quality, regulatory, and safety domains. For more information on Veeva RIM, visit Veeva's official site.

About Veeva Systems

Veeva specializes in offering cloud services tailored specifically for the life sciences industry, providing software, data, and business consulting. With a commitment to innovation and ensuring customer success, Veeva serves over 1,500 companies, ranging from the largest biopharmaceutical firms to emerging biotech businesses. As a Public Benefit Corporation, Veeva also aims to balance the interests of all stakeholders, including customers, employees, and shareholders within the industry. Learn more at www.veeva.com/jp/.

Stay Updated

For updates and information about Veeva, connect with them on LinkedIn.

Forward-Looking Statements

This article includes forward-looking statements regarding Veeva's products and services and the anticipated benefits from their use. These statements reflect current expectations and actual results may differ materially. For risks affecting our business, refer to our filings with the SEC.